Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

Introduction: The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment. However, ultimately many patients still relapse,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fagnano, Ester, Pendharkar, Swati, Colton, Madyson, Jones, Philip N., Sallan, Marta Crespi, Klymenko, Tetyana, Braun, Andrejs, Klein, Christian, Honeychurch, Jamie, Cheadle, Eleanor J., Illidge, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646167/
https://www.ncbi.nlm.nih.gov/pubmed/38020903
http://dx.doi.org/10.3389/fcell.2023.1270398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646167/
https://www.ncbi.nlm.nih.gov/pubmed/38020903
http://dx.doi.org/10.3389/fcell.2023.1270398

Ejemplares similares